Outlook Therapeutics, Inc. OTLK 深 滬
等待開盤 11-26 09:30:00 美东时间
1.60
-0.200
-11.11%
華盛通- 最 高1.84
- 今 開1.84
- 成交量 538.77万股
- 最 低 1.59
- 昨 收 1.80
- 總市值 6856.59万
- 52周最高 3.39
- 市盈率 靜 --
- 換手率 12.57%
- 52周最低 0.79
- 委 比 78.91%
- 總股本 4285.37万
- 歷史最高 219.20
- 量 比 1.41
- 振 幅 13.89%
- 歷史最低 0.79
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Outlook Therapeutics' CEO, Bob Jahr, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:00 AM ET. A live webcast of the chat will be available on the company's website, with a replay archived for 90 days. Management will also host one-on-one meetings with investors. Outlook Therapeutics focuses on developing LYTENAVA™ for treating retinal diseases, which is the first approved opht...
11-24 14:05
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 205.0% to $27.05...
11-14 01:06
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics announced that the FDA has accepted the resubmission of the BLA for ONS-5010 (bevacizumab-vikg) for wet AMD treatment. The PDUFA goal date is set for December 31, 2025. If approved, ONS-5010 will be marketed as LYTENAVA™, the first FDA-approved ophthalmic bevacizumab formulation in the U.S. The company addressed feedback from the August 2025 CRL and expects a 60-day review period. LYTENAVA™ is already authorized in Europe and...
11-13 13:30
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Outlook Therapeutics has resubmitted its BLA to the FDA for ONS-5010, an ophthalmic formulation of bevacizumab aimed at treating wet AMD, following feedback from a September 2025 Type A meeting. The company believes this action addresses the issues highlighted in the August 2025 CRL. CEO Bob Jahr emphasized the importance of this step in achieving U.S. approval and highlighted ongoing European commercialization efforts. ONS-5010, branded as LYTEN...
11-03 13:35
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
HC Wainwright & Co. Reiterates Neutral on Outlook Therapeutics, Maintains $1 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $1 price target.
09-30 19:41
Outlook Therapeutics Completes FDA Meeting on ONS-5010
Outlook Therapeutics ( ($OTLK) ) just unveiled an announcement. On September 29...
09-30 05:33
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $8
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target from $21 to $8.
09-22 17:30
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
- **出席活动** Outlook Therapeutics Inc. 将于2025年9月3日在巴黎举行的第25届EURETINA大会上，参加EURETINA Innovation Spotlight活动，演讲题目为"Optimising the treatment of retinal disease"，由CEO Bob Jahr博士主讲。 - **公司简介** Outlook Therapeutics专注于开发眼科用药LYTENAVA™，这是首个获得欧洲和英国批准用于治疗湿性AMD的贝伐珠单抗制剂。在美国该产品正处于临床研究阶段，若获准将是首个用于治疗视网膜疾病的贝伐珠单抗眼科制剂。
09-03 12:35
